First in Human Trial of CTX-187 in Healthy Volunteers and Chronically Infected Patients

计划入组 104 人 · 首次发布于 2026 年 7 月 16 日

Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)

计划入组 19 人 · 首次发布于 2020 年 2 月 17 日

Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma

计划入组 54 人 · 首次发布于 2026 年 2 月 6 日

SXN-187

NGD-187

TAK-187

Rigenerand Srl

Italy

Medpointe Pharmaceuticals

United States

QPS Holdings LLC

United States

Centauri Therapeutics Secures £6M from AMR Action Fund to Advance Novel Antibiotic CTX-187 Through Phase I Trials

Compass Therapeutics' CTX-471 Shows Promise with NCAM Biomarker Correlation in Advanced Malignancies

FDA Clears Path for Cingulate's CTx-1301 ADHD Treatment NDA Submission